CLDND2 Inhibitors
Chemical compounds that inhibit the functional activity of CLDND2 do so by interacting with various pathways and cellular processes that are pivotal for the protein's proper localization, expression, and function. Colchicine and paclitaxel target the microtubule dynamics that are essential for intracellular trafficking, which is necessary for the correct localization and function of CLDND2. Disruption of microtubules by colchicine or abnormal stabilization by paclitaxel can lead to mislocalization of CLDND2, impairing its function. Similarly, compounds like blebbistatin and Y-27632 disrupt the actin cytoskeleton and cell contractility, respectively. Bydisrupting the actin cytoskeleton, these compounds can interfere with the cellular infrastructure that supports the movement and positioning of CLDND2. Since the actin network is closely tied to various cellular processes, including vesicle trafficking, cell motility, and structure maintenance, the inhibition of actin dynamics can lead to a functional impairment of CLDND2.
For instance, blebbistatin, by inhibiting myosin II, can prevent the proper functioning of the motor proteins that facilitate the movement of cellular components along the actin filaments. This can disrupt the normal trafficking and localization of CLDND2 within the cell. Y-27632, on the other hand, by inhibiting ROCK, can relax the cell's contractile machinery and thus alter the tension within the cell. This could affect not only the cell shape and motility but also the distribution and function of CLDND2, as the protein may rely on a certain cellular architecture for its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine disrupts microtubule polymerization by binding to tubulin, one of the main constituents of microtubules. Given that CLDND2 is associated with cellular structures and processes that require intact microtubules for trafficking and localization, the disruption of microtubules can lead to impaired CLDND2 function. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and prevents their disassembly, which can disrupt normal microtubule dynamics. Since the function of CLDND2 is related to the cytoskeletal structure, an abnormal stabilization of microtubules can hinder the normal trafficking and function of CLDND2. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
Blebbistatin is an inhibitor of myosin II, which is crucial for muscle contraction and cell motility. By inhibiting myosin II, blebbistatin could potentially impair cellular processes that depend on myosin, leading to altered cellular distribution or function of CLDND2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a potent inhibitor of ROCK (Rho-associated protein kinase), which plays a significant role in actin cytoskeleton organization. Inhibition of ROCK can lead to changes in cytoskeletal structure and cell morphology, potentially affecting the localization and function of CLDND2. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), which is involved in the regulation of the actomyosin contractile apparatus. Inhibition of MLCK can result in a decrease in cellular tension and might impinge on the proper distribution and function of CLDND2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is a kinase involved in the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can downregulate ERK activity, which could affect the phosphorylation status of proteins associated with the pathway, potentially impacting the function of CLDND2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a key role in multiple cellular processes, including cell growth and survival. Inhibition of PI3K signaling can affect downstream effectors that may interact with or modulate the function of CLDND2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, similar to Wortmannin. It prevents the phosphorylation of PI3K substrates, leading to a decrease in PI3K signaling, which can affect the function of proteins associated with this pathway, including CLDND2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is an inhibitor of p38 MAP kinase, a protein involved in response to stress and cytokines. By inhibiting p38 MAP kinase, SB 203580 can alter the cellular response to stress and inflammation, potentially affecting the function of CLDND2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the control of gene expression and cell survival. Inhibition of JNK signaling can lead to altered transcriptional regulation of proteins that may interact with or affect the functionality of CLDND2. | ||||||